Serum PCSK9 levels appear elevated in patients with autoimmune liver diseases such as primary biliary cholangitis (PBC), meaning patients may benefit from an earlier diagnosis even when routine liver tests look normal, according to a study published recently in Scientific Reports.
Because PBC is central to this group of disorders, researchers evaluated how PCSK9 relates to PBC in the very first step of the analysis and found a consistent connection throughout. The findings suggest that PCSK9, a protein known for regulating cholesterol, may become a useful biomarker for identifying disease at an earlier stage, which could help patients begin monitoring and treatment sooner.
In this study, 100 adults with autoimmune liver diseases — 57 with primary sclerosing cholangitis (PSC), 33 with PBC and 10 with autoimmune hepatitis — were compared with 88 healthy controls. PCSK9 levels were considerably higher in every patient group than in healthy individuals. This held true even for patients with liver disease whose liver enzyme and cholestasis markers were close to normal.
“Importantly, PCSK9 showed good diagnostic performance, particularly in male patients with PSC and female patients with PBC, and may serve as a complementary biomarker in the diagnostic evaluation of autoimmune liver diseases,” explained this study’s authors.
Read more about causes and risk factors for PBC
Sex-specific patterns also emerged. In women, PCSK9 values clearly distinguished patients with PBC from healthy controls. In men, PCSK9 effectively identified PSC. These distinctions matter for patients because PBC affects mostly women and PSC affects mostly men, so a reliable signal tied to each condition could help reduce delays in reaching a diagnosis.
Importantly for patients, PCSK9 levels did not track with cholesterol levels, liver damage scores, fibrosis or Model of End Stage Liver Disease (MELD) scores. This means a patient with PBC or another autoimmune liver disease could have high PCSK9 even if their cholesterol or routine labs appear normal. PCSK9 also did not predict which patients would later experience decompensation or require a transplant, although three PBC patients who needed a transplant had higher levels.
While PCSK9 cannot yet guide prognosis or treatment choice, its consistent elevation, especially in PBC, shows promise as a diagnostic aid. Further research will need to confirm how best to use PCSK9 testing so patients can receive answers and care earlier in their disease course.
Sign up here to get the latest news, perspectives, and information about PBC sent directly to your inbox. Registration is free and only takes a minute.
